France-based Flamel Technologies and Merck Serono have shook hands
on a new €2m ($2.9m) deal which would see Flamel's Medusa
technology used to develop an extended-release profile of an
undisclosed therapeutic protein.
Scientists have discovered a potential new drug target that will prick up the ears of sportsmen and athletes alike. Not that this is an performance-enhancing drug; instead, it could help athletes recover from injury more quickly.